Neoadjuvant Trastuzumab and Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer


Neoadjuvant Trastuzumab and Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Untch M et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow-up data of the TECHNO trial. San Antonio Breast Cancer Symposium 2010;Abstract P1-11-03.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.